Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Ignyta, Inc. (RXDX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/14/2017 |
8-K
| Form 8-K - Current report |
| 05/10/2016 |
8-K
| Quarterly results |
| 03/14/2016 |
8-K
| Form 8-K - Current report |
| 11/09/2015 |
8-K
| Investor presentation, Quarterly results |
| 08/10/2015 |
8-K
| Quarterly results |
| 05/11/2015 |
8-K
| Quarterly results |
| 11/07/2014 |
8-K
| Quarterly results |
| 08/12/2014 |
8-K
| Quarterly results |
| 05/12/2014 |
8-K
| Quarterly results |
| 02/28/2014 |
8-K
| Quarterly results|
Docs:
|
"Ignyta Announces 2013 Company Highlights and Full Year Financial Results February 28, 2014 1:00 PM Eastern Time SAN DIEGO——Ignyta, Inc. , an oncology precision medicine biotechnology company, today announced financial results for the full year ended December 31, 2013. “2013 was a transformational year for Ignyta, as we focused the business on oncology precision medicine, in-licensed two proprietary oral tyrosine kinase inhibitor product candidates, became a publicly-traded company through our reverse merger transaction and raised substantial capital to bolster our balance sheet,” said Jonathan Lim, M.D., Chairman and CEO of Ignyta. “We intend to build on that momentum in 2014 as we strive to develop improved treatment options for patients with our proprietary oncology drug candidates and o..." |
|
|
|